Venetoclax is a BH3 mimetic developed as a highly specific inhibitor of BCL-2 with very low affinity for BCL-XL, unlike the predecessor ABT263 (navitoclax), which additionally inhibits BCL-XL, leading to dose-dependent induction of thrombocytopenia [3]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.